DEA delays kratom ban, more Senators object to process and ‘unintended consequences’
“The alkaloids have been known for over a decade to possess some modest opioid actions but their potential benefit for patients with chronic pain and substance dependence was overlooked in the (DEA) notice of intent to place the botanical chemicals in the same class as heroin, LSD and mescaline.”
Columbia associate research scientist, Andrew Kruegel, PhD, was specifically cited in the Booker-Gillibrand-Wyden letter to DEA as he led an 11-scientist letter of objection to kratom scheduling that was submitted to congressional representatives on September 2. Kruegel is also first author on a paper published in the Journal of the American Chemical Society in May showing the alkaloids in kratom act on opioid receptor signal transmission entirely differently than strong opioids such as morphine, fentanyl and oxycodone, posing less risk of respiratory depression.
Original Article (Forbes):
DEA delays kratom ban, more Senators object to process and ‘unintended consequences’.
Artwork Fair Use: ThorPorre